Glioblastoma Multiforme (GBM) Treatment Market Insights: Gene Therapy and CAR-T Innovation Drive the Future

The global Glioblastoma Multiforme (GBM) Treatment Market is gaining momentum as the rising incidence of aggressive brain tumors increases demand for advanced oncology therapies. The market was valued at USD 2.88 billion in 2025 and is projected to grow from USD 3.1 billion in 2026 to USD 5.52 billion by 2034, registering a CAGR of 7.5% during the forecast period.

• Market Size (2025): USD 2.88 Billion
• Market Size (2026): USD 3.1 Billion
• CAGR (2026–2034): 7.5%
• Forecast Year: 2034
• Projected Market Size (2034): USD 5.52 Billion
• Dominant Region: North America
• Fastest Growing Region: Europe

Market Overview

Glioblastoma multiforme is one of the most aggressive forms of brain cancer, commonly classified as a grade IV astrocytoma. The disease progresses rapidly, invades nearby brain tissue, and is associated with severe symptoms such as headaches, seizures, and neurological decline.

Current treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy. Although treatment outcomes remain challenging, continued innovation in oncology research is improving therapeutic approaches and creating new market opportunities.

Growth Drivers

The increasing incidence of brain and central nervous system cancers is a major driver of market growth. Glioblastoma remains one of the most common malignant brain tumors, with higher prevalence among adults and elderly populations.

Rising approvals for novel therapies and combination treatments are also supporting market expansion. Fast-track designations, orphan drug approvals, biosimilar launches, and personalized treatment approaches are expected to improve patient outcomes and increase treatment adoption.

Market Challenges

The lack of highly effective therapies remains a key restraint. Existing treatments often provide limited survival benefits, and glioblastoma continues to show strong resistance to standard therapies.

High treatment complexity, neurotoxicity risks, and low long-term survival rates continue to create significant challenges for healthcare providers and pharmaceutical companies.

Market Opportunities

Increasing research and development activity is creating strong opportunities in the GBM treatment market. Companies are investing in targeted therapies, immunotherapies, RNA-based therapies, gene therapies, and CAR-T cell treatments to improve survival outcomes.

Collaborations between biotechnology companies, pharmaceutical firms, academic institutions, and research centers are expected to accelerate the development of next-generation glioblastoma therapies.

Segment Analysis

By treatment, radiation therapy holds the largest market share due to its established role in managing GBM and improving survival when combined with chemotherapy.

By drug, temozolomide dominates the market. Its ability to cross the blood-brain barrier and its use in combination with radiation therapy make it a widely prescribed treatment for newly diagnosed GBM.

By end-user, hospitals lead the market because GBM treatment often requires complex surgical procedures, advanced oncology care, emergency services, and multidisciplinary clinical support.

Regional Analysis

North America dominates the global market due to advanced healthcare infrastructure, strong reimbursement systems, high awareness of rare cancers, and active government support for oncology research.

Europe is expected to be the fastest-growing region, supported by rising awareness campaigns, research funding, neuro-oncology initiatives, and increasing clinical development activities across major countries.

Competitive Landscape

Key companies operating in the market include:

• Merck & Co. Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Arbor Pharmaceuticals LLC
• Karyopharm Therapeutics Inc.
• Amneal Pharmaceuticals
• Sumitomo Dainippon Pharma Oncology Inc.

Recent Developments

In June 2023, Chimeric Therapeutics initiated a Phase IB clinical trial of CHM 1101 cell therapy for patients with recurring or progressive glioblastoma multiforme.

In May 2023, Rznomics Inc. received U.S. FDA phase 1/2a IND approval for its RNA-based glioblastoma multiforme treatment.

Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/glioblastoma-multiforme-treatment-market

Future Outlook

The global Glioblastoma Multiforme Treatment Market is expected to grow steadily through 2034 as pharmaceutical companies focus on precision medicine, immunotherapy, gene-based treatments, and advanced drug delivery systems.

Although GBM remains one of the most difficult cancers to treat, rising R&D investments, expanding clinical trials, and regulatory support for innovative therapies are expected to improve the long-term market outlook.

About Straits Research

Straits Research is a global market intelligence and consulting company providing in-depth market research, industry analysis, competitive intelligence, and strategic insights. The company helps businesses understand market trends, evaluate growth opportunities, and make informed decisions across global industries.